Preview

Онкоурология

Расширенный поиск

Радионуклидная терапия в лечении больных раком предстательной железы с метастазами в кости

https://doi.org/10.17650/1726-9776-2006-2-1-61-68

Об авторах

В. В. Крылов
ГУ МРНЦ РАМН
Россия
Обнинск


О. Б. Карякин
ГУ МРНЦ РАМН
Россия
Обнинск


Б. Я. Дроздовский
ГУ МРНЦ РАМН
Россия
Обнинск


Список литературы

1. Модников О.П., Новиков Г.А., Родионов В.В. Современные подходы к лечению множественного метастатического поражения костей // Курс лекций по паллиативной помощи онкологическим больным / Под ред. Г.А Новикова., В.И. Чиссова, О.П. Модникова. – М., 2004. – Т. 1. – С. 493–541.

2. Enrique O., Zhongyun P., Parma E.P. et al. Efficacy and toxicity of Sm-153-EDTMP in the palliative treatment of painful bone metastases // World J. Nucl. Med. – 2002; 1 (1):21–27.

3. Исакова М.Е. Проблема боли в онкологии // РМЖ. – 2000. – Т. 8, №17.

4. Кондратьева А.П. Новое в лечении костных метастазов // РМЖ. – 1999. – Т.7, №10.

5. Моисеенко В.М., Блинов Н.Н. Современная тактика лечения больных злокачественными новообразованиями с метастазами в кости. Пособие для врачей. – СПб., 1996.

6. Нестеренко В.М., Новиков Г.А., Борисов В.И. Причины развития, типы и клинические проявления костных метастазов // Паллиативная медицина и реабилитация. – 1998. – №6. – С. 38–41.

7. Chakraborty S., Das T., Unni P.R. et al. 177Lu labelled polyaminopshonates as potential agents for bone pain palliation // Nuc. Med. Communications. – 2002; 23: 67—74.

8. Turner J.H. Treatment of painful skeletal metastases // Alasbimn J. Special Issue: 8-th World Congress of Nuclear Medicine. – 2002; Sept. 17.

9. Корытова Л.И., Сухов В.Ю., Шутко А.Н., Карелин М.И., Хозова Т.В. Применение «Метастрона» в лечении больных с костными метастазами. Пособие для врачей. – СПб., 1997.

10. Ли Л.А. Клиника, диагностика и лечение метастазов рака молочной железы. Пособие для врачей. – Л., 1990.

11. Цыб А.Ф., Дроздовский Б.Я., Крылов В.В., Кодина Г.Е. Паллиативная терапия самарием-оксабифором, 153Sm при метастатических поражениях костей // Медицинская радиология и радиационная безопасность. – 2002. – Т. 48, №4.

12. Cleeland Ch.S., Conin R., Hotfield H.K. et al. Pain and its treatment in outpatrents with metastatic cancer // N. Eng. J. Med. – 1994; 330,592–596.

13. Boissier S., Ferreras M., Peyruchaud O. et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases // Cancer Res. – 2000; 60:2949–2954.

14. Nussbaum S.R., Younger I. et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalciemia of malignancy: comparison of 30-, 60-, and 90-mg dosages // Am. J. Med. – 1993; 95:297–304.

15. Coleman R.E., Purohit O.P. Osteoclast inhibition for the treatment of bone metastases // Cancer. Treat. Rev. – 1993;19:79–103.

16. Fettich J., Padhy A., Nair N., Morales R. et al. Comparative clinical efficacy and safety of 32P and 89Sr in the palliative treatment of metastatic Bone Pain: results of an IAEA coordinated research project // World Nucl. Med. – 2003; 2 (3):226–231.

17. Hoegler D. Radiotherapy for palliation of symptoms in incurable cancer // Curr. Probl. Cancer. – 1997; 21 (3), 129–183.

18. Hoefnagel C.A., Clarke S.E.M., Fischer M. et al. Radionuclide therapy practice and facilities in Europe // Eur. J. Nucl. Med. – 1999; 26: 277–282.

19. Anderson P.M., Wiseman G.A., Dispenzieri A. et al. High-dose samarium-153 ethylenediaminetetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases // J. Clin. Oncol. – 2002; 20:1, 189–196.

20. Bishayee A., Rao D.V., Srivastava C. et al. Marrow-sparing effects of 117m Sn (4+) diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer // J. Nucl. Med. – 2000; 41:2043–2050.

21. Goddu S.M., Bishayee A., Bouchet L.G. et al. Marrow toxicity of 33P versus 32P-Orthophosphate: implications for therapy of bone pain and bone metastases // J. Nucl. Med. – 2000; 41:5, 941–951.

22. Ketring A. 153Sm-EDTMP and 186ReHEDP as bone therapeutic radiopharmaceuticals // Nucl. Med. Biol. – 1987; 14:223–232.

23. Krishnamurthy G.T., Krishnamurthy S. Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium // J. Nucl Med. – 2000; 41 (4):688–691.

24. Liepe K., Hliscs R., Kropp J. et al. Rhenium-188 HEDP in the palliative treatment of bone metastases // Cancer Biotherapy & Radiopharmaceuticals. – 2000; 15(3):261–265.

25. Maxon H., Schroder L., Washurn L. Rhenium-188 HEDP for treatment of osseous metastases // J. Nucl. Med. – 1998; 39:659–663.

26. Mc Ewan A.J. et al. A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone // Eur. Urol. – 1994; 26 (1):26–31.

27. Schmeler H., Bastin K. Strontium-89 for symptomatic metastatic prostate cancer in bone: Recommendations for hospice patients // The Hospice J. – 1996; 11:2–10.

28. Holmes R. [153Sm] EDTMP: A Potential Therapy for Bone Cancer Pain // Seminars in Nucl. Med. – 1992. – V. XXII, №1. – P. 41–45.

29. Oh S.J., Won K.S., Moon D.H. et al. Preparation and biological evaluation of 188Re-ethylenediamine-N,N,N1,N1- tetrakis (methylenephosphonic acid) as a potential agent for bone pain palliation // Nucl. Med. Communications. – 2002; 23:75–81.

30. Nair N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases // J. Nucl. Med. – 1999; 40:256–-261.

31. Palmedo H., Bender H., DierkeDzierzon C. et al. Pain palliation with rhenium-186-HEDP in breast cancer patients with disseminated bone metastases // Clin. Nucl. Med. – 1999; 24:643–648.

32. Robinson RG., Spicer J.A., Preston D.F. et al. Treatment of metastatic bone pain with strontium-89 // Nucl. Med. Biol. – 1987; 14:219–222.

33. Sevilla A., Salgado L., Fonseca A.T., Vieira M.R. Is early Sr-89-Therapy useful in prostate cancer patient with bone metastasis? // World J. Nucl. Med. – 2002; 1 (2): 276.

34. Resche I., Chatal J.-F., Pecking A. et al. A dose-controlled study of 153SmEthylenediaminetetramethylenephosphona te (EDTMP) in the treatment of patients with painful bone metastases // Eur. J. Cancer. – 1997; 33(10):1583–1591.

35. Bayouth J.E., Macey D.J., Kasi L.P., Fossella F.V. Dosimetry and Toxicity of Samarium-153-EDTMP Administried for Bone Pain Due to skeletal metastases // J. Nucl. Med. – 1994; 35: 63–69.

36. Eary J.F., Collins C., Stabin M. et al. Samarium- 153-EDTMP biodistribution and dosimetry estimation // J. Nucl. Med. – 1993; 34:1031–1036.

37. Farhangi M., Holmes R.A., Volkert W.A. et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer // J. Nucl. Med. – 1992; 33;1451–1458.

38. Collins C., Eary J.F., Donaldson G. et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial // J. Nucl. Med. – 1993;.34;1839–1844.

39. Sciuto R., Tofani A., Festa A. et al. Short and long-term effects of 186Re-1, 1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases // J. Nucl. Med. – 2000; 41:647–654.

40. Kaplan E. Historical development of P-32 in bony therapy / Spencer R.P. (ed): Therapy in Nuclear Medicine. – Philadelphia, PA, Saunders, 1978. – P. 237–249.

41. Johnson D.E., Haynie T.P. Phosphorus- 32 for untreatable pain in carcinoma of prostate. Analysis and androgen primary, parathormone, rebound and combination therapy // J. Urol. – 1977; 9:137–139.

42. Han S. H., de Klerk J.M.N., Tan.S. et al. The Placorhen Stady: a double-blind, placebo controlled, randomized radionuklide study with Re-186-Etidronate in hormono-resistant prostate cancer patients with painful bone metastases // J. Nucl. Med. – 2002. – V. 43., №9. – 1150–1156.

43. Limouris G., Shukia S., Manetou A. et al. Rhenium-186-HEDP-palliative treatment in disseminated bone metastases due to prostate cancer // Anticancer Res. – 1997; 17:1699–1704.

44. Srivastava S.C., Atkins H.L., Krishnamurthy G.T. et al. Treatment of metastatic bone pain with tin-117m stannic diethylenetriamine pentaacetic acid: a phase I/II clinical study // Clin. Cancer Res. – 1998; 4:61–68.

45. Lin W.-Y., Lin C.-P., Yeh S.-J. et al. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases // Eur. J. Nucl. Med. – 1997; 24:590–595.

46. Lewington V.J. Cancer therapy using bone-seeking isotopes // Phys. Med. Biol. – 1996; 41:2027–2042.

47. Palmedo H., Guhlke S., Bender H. et al. Dose escalation study with Re-188 HEDP in prostate cancer patients with osseous metastases // J. Nucl. Med. – 1999; 5:218P.

48. Mertens W.C., Stitt L., Porter A.T. Strontium-89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: A dose response relationship // Am. J. Clin. Oncol. – 1993; 16(3): 238–242.

49. Silberstein E.B., Buscombe J.R., Mc. Ewans A., Taylor A.T. Society of nuclear medicine procedure guideline for palliative treatment of painful bone metastases // Society of nuclear medicine procedure guidelines manual. – 2003. – P. 145 – 153.

50. Robinson RG. Radionuclides for the alleviation of bone pain in advanced malignancy // Clin. Oncol. – 1986; 5:39–49.

51. Serafini A.N., Kuker R.A., Fernandez G. et al. Evaluation of Sm-153 EDTMP as a Tumoricidal Agent in Prostate Cancer // World J. Nucl. Med. – 2002; 1 (2):136.

52. Sinzinger H., Weiss K., Granegger S., Hajek C. Repeated low-dose vs. single higtdose 153 EDTMP treatment. Advantages and disadvantages // World J. Nucl. Med. – 2002; 1 (2):69.

53. Ferretti G., Povolato M., Bisssoli S. 89-SrCl and 153-Sm EDTMP radiometabolic treatment of metastatic bone pain (MBP) in prostate cancer (PC): our experience // Alasbimn J. – Special Issue: 8-th World Congress of Nuclear Medicine. – 2002; sept. 17.


Рецензия

Для цитирования:


Крылов В.В., Карякин О.Б., Дроздовский Б.Я. Радионуклидная терапия в лечении больных раком предстательной железы с метастазами в кости. Онкоурология. 2006;2(1):61-68. https://doi.org/10.17650/1726-9776-2006-2-1-61-68

For citation:


Krylov V.V., Karyakin O.B., Drozdovsky B.Ya. Radionuclide therapy in the treatment of patients with prostatic cancer with metastases in the bones. Cancer Urology. 2006;2(1):61-68. (In Russ.) https://doi.org/10.17650/1726-9776-2006-2-1-61-68

Просмотров: 309


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X